GlassScriptPhysician profile
Elizabeth A Barron
NPI 1912998253
$4,323.91
in general payments reported to CMS, 2019-2025
37 companies · $605 in 2025
The $605 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $453 · 2021: $613 · 2022: $684 · 2023: $843 · 2024: $481 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,929.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $505.74 | 2019-2023 | Liletta, Orilissa, Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $243.29 | 2019-2025 | |
| Pfizer INC. | $238.22 | 2019-2025 | |
| Baxter Healthcare | $203.15 | 2020-2024 | Perclot |
| Exeltis, USA INC. | $191.49 | 2019-2025 | Slynd |
| Evofem Biosciences, INC. | $188.73 | 2020-2023 | Phexxi |
| Shield Therapeutics INC | $182.50 | 2022-2025 | Accrufer |
| Sage Therapeutics, LLC | $181.71 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $171.40 | 2021-2025 | |
| Organon LLC | $162.10 | 2022-2025 | Nexplanon, Jada System |
| Coopersurgical, INC. | $161.58 | 2019-2020 | |
| Ethicon US, LLC | $154.66 | 2023-2025 | Dermabond Prineo, Stratafix, Enseal |
| Therapeuticsmd, INC. | $142.33 | 2019-2022 | |
| Exact Sciences Corporation | $138.79 | 2023-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $136.21 | 2019-2023 | Acessa Provu System, Aptima |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $130.67 | 2023-2025 | Intrarosa, Femlyv |
| Mylan Pharmaceuticals INC. | $121.88 | 2019-2022 | |
| Myriad Women'S Health, INC. | $109.38 | 2023 | Myrisk |
| Avion Pharmaceuticals | $104.54 | 2020-2023 | Balcoltra |
| Astellas Pharma US INC | $79.62 | 2023-2025 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $78.67 | 2020-2022 | |
| Biogen, INC. | $74.86 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $70.29 | 2021-2023 | Twirla |
| Amag Pharmaceuticals, INC. | $67.72 | 2019-2020 | |
| Aspira Women'S Health INC | $67.67 | 2021 | |
| Sumitomo Pharma America, INC. | $67.16 | 2023 | Myfembree |
| Myovant Sciences INC. | $65.99 | 2021-2022 | |
| Minerva Surgical, INC | $57.86 | 2019-2024 | |
| Duchesnay USA Incorporated | $49.32 | 2019 | |
| Amgen INC. | $43.96 | 2019 | |
| Siemens Medical Solutions USA, INC. | $28.05 | 2022 | |
| Allergan, INC. | $23.88 | 2020 | |
| Supernus Pharmaceuticals, INC. | $19.60 | 2025 | Qelbree |
| Monaghan Medical Corporation | $19.55 | 2023 | Aerobika |
| Scynexis, INC. | $15.17 | 2022 | |
| Lupin INC. | $14.21 | 2021 | |
| Merck Sharp & Dohme LLC | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Barron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.